iSpecimen Inc. Raises $1.75 Million Through At-Market Private Placement to Bolster Marketing and Corporate Purposes
PorAinvest
miércoles, 6 de agosto de 2025, 2:26 pm ET1 min de lectura
ISPC--
The funds raised will be used to bolster marketing efforts, with $500,000 allocated to marketing and advertising services through IR Agency LLC. The remaining $1.25 million will support working capital and general corporate purposes. WestPark Capital served as the exclusive placement agent for the offering, which closed on August 4, 2025 [2].
iSpecimen's platform connects scientists with healthcare providers, enabling efficient access to necessary biospecimens for medical research and discovery. The company's proprietary, cloud-based technology allows scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations [3].
The private placement was exclusively available to accredited investors and will require subsequent SEC registration for potential resale. Additional details regarding the offering will be available in a Form 8-K filing with the SEC [1].
References:
[1] https://www.globenewswire.com/news-release/2025/08/04/3126989/0/en/iSpecimen-Inc-Announces-Closing-of-Approximately-1-75-Million-Private-Placement-Priced-At-the-Market.html
[2] https://www.gurufocus.com/news/3023707/ispecimen-inc-announces-pricing-of-approximately-175-million-private-placement-priced-atthemarket-ispc-stock-news
[3] https://www.stocktitan.net/news/ISPC/i-specimen-inc-announces-closing-of-approximately-1-75-million-1ebr32zcwmw7.html
iSpecimen Inc. (ISPC) closed a $1.75 million private placement, issuing 1.56 million shares of common stock and pre-funded warrants at $1.122 each. Funds will bolster marketing efforts and general corporate purposes. WestPark Capital served as the exclusive placement agent. The transaction closed on August 4, 2025, and details will be disclosed in a Form 8-K filing with the SEC.
iSpecimen Inc. (ISPC), an online marketplace for human biospecimens, has successfully closed a $1.75 million private placement. The company issued 1,559,828 shares of common stock and pre-funded warrants at a price of $1.122 per share, aligning with Nasdaq's at-the-market pricing rules [1].The funds raised will be used to bolster marketing efforts, with $500,000 allocated to marketing and advertising services through IR Agency LLC. The remaining $1.25 million will support working capital and general corporate purposes. WestPark Capital served as the exclusive placement agent for the offering, which closed on August 4, 2025 [2].
iSpecimen's platform connects scientists with healthcare providers, enabling efficient access to necessary biospecimens for medical research and discovery. The company's proprietary, cloud-based technology allows scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations [3].
The private placement was exclusively available to accredited investors and will require subsequent SEC registration for potential resale. Additional details regarding the offering will be available in a Form 8-K filing with the SEC [1].
References:
[1] https://www.globenewswire.com/news-release/2025/08/04/3126989/0/en/iSpecimen-Inc-Announces-Closing-of-Approximately-1-75-Million-Private-Placement-Priced-At-the-Market.html
[2] https://www.gurufocus.com/news/3023707/ispecimen-inc-announces-pricing-of-approximately-175-million-private-placement-priced-atthemarket-ispc-stock-news
[3] https://www.stocktitan.net/news/ISPC/i-specimen-inc-announces-closing-of-approximately-1-75-million-1ebr32zcwmw7.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios